BioDuro Appoints Alan Findlater as New Chief Commercial Officer

CRDMO BioDuro has announced the appointment of Alan Findlater as their new CCO, who brings over 25 years of senior commercial leadership experience in the life sciences and pharmaceutical services industry to his new role. Findlater has experience leading high-performing teams and managing complex product and service portfolios, with his expertise also extending to executing successful strategic growth initiatives on a global scale and building high-value partnerships with industry leaders such as Amgen, Pfizer, and Roche.

BioDuro, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced the appointment of Alan Findlater as Chief Commercial Officer.

With over 25 years of senior commercial leadership experience in the life sciences and pharmaceutical services industry, Findlater brings a proven track record of leading high-performing teams of up to 150 professionals, managing complex product and service portfolios, building high-value partnerships with industry leaders including Amgen, Pfizer and Roche, and executing successful strategic growth initiatives on a global scale.

Findlater holds a bachelor's in chemistry from the University of Strathclyde and an MBA from Warwick Business School, both in the UK.

“We are thrilled to welcome Alan Findlater to the BioDuro executive team,” said Dr. Armin Spura, CEO of BioDuro. “Alan's vast experience and successful track record in the life sciences industry will be invaluable as we continue to enhance our commercial strategy, drive commercial success, and deliver innovative client-centric solutions that strengthen our market leadership.”

For more, please find the original story source here.

Previous
Previous

Outsource or Die? How CDMOs Will Shape Pharma in 2025 and Beyond

Next
Next

KPMG Life Sciences CEO Outlook Report